Dr. Lekakis on Current Research With CAR T-Cell Therapy

Video

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Bispecific CAR T cells are an area of active investigation in B-cell malignancies, explains Lekakis. Currently, tisagenlecleucel (Kymriah) and axicabtagene-ciloleucel (Yescarta) are approved for patients with relapsed or refractory diffuse large B-cell lymphoma, both of which target CD19. Some of the dual targets under investigation include CD19 and CD22. Dual-targeted CAR T cells may be more effective, explains Lekakis as CAR T-cell evasion can occur with CD19 clones, he explains.

In multiple myeloma, several products are under investigation—–all of which target BCMA. Some companies are combining CAR T cells with PD-1/PD-L1 inhibitors to try to evade T-cell exhaustion, explains Lekakis. Combinations of CD19-specific CAR T cells and lenalidomide (Revlimid) and rituximab (Rituxan) are also under exploration, adds Lekakis.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS